Europe Watch

March 2007
ICIS Chemical Business;3/26/2007, Vol. 2 Issue 59, p10
Trade Publication
The article reports that pharmaceutical firm Bayer has reached agreement with the works council at the new Bayer Schering Pharma on a socially acceptable plan for implementing the planned 6,100 merger-related job cuts. Employee representatives had threatened to torpedo the integration of the two healthcare businesses, saying that the former Schering's workforce was bearing the brunt of the cuts.


Related Articles

  • Works council threatens to scupper Bayer merger. Williams, Dede; Gibson, Jane // ICIS Chemical Business;3/12/2007, Vol. 2 Issue 57, p12 

    The article reports that the works council at Bayer Schering Pharma has threatened to end the integration of the two formerly independent companies, Bayer and Schering, in protest of over 6,100 planned job cuts. The council is demanding a staff meeting before March 13, 2007. Berlin, Germany...

  • Bayer Schering job cuts. William, Dede; Gibson, Jane // ICIS Chemical Business Americas;3/5/2007, Vol. 271 Issue 9, p13 

    This article reports that Schering is set to cut 950 jobs at its headquarters in Berlin, Germany by 2009. Werner Wenning, Bayer chairman, said the move is due to the merger between the pharmaceutical activities of Schering and Bayer. Wenning, who is also chairman of Bayer Schering Pharma's...

  • Europe watch.  // ICIS Chemical Business Americas;3/26/2007, Vol. 271 Issue 12, p14 

    The article presents news briefs on chemical producer Bayer as of March 2007. The company reached an agreement with the works council at the Bayer Schering Pharma on an acceptable plan for implementing its job cuts after their merger. Bayer paid $1.2 billion as settlement for 3,152 out-of-court...

  • Bayer completes acquisition of U.S biologics manufacturing facility from Novartis.  // Chemical Business;Oct2007, Vol. 21 Issue 10, p75 

    The article reports on the acquisition by Bayer of a biologics manufacturing facility in California from Novartis in October 2007. Under the deal, the drug Betaseron will be manufactured by Bayer, retain all employees involved in the production of the drug. Reportedly, Novartis has also...

  • DATAMONITOR: Bayer Schering Pharma AG.  // Schering AG SWOT Analysis;Jul2009, p1 

    A company profile of Bayer Schering Pharma A.G., a global pharmaceutical company which is a wholly owned subsidiary of Bayer headquartered in Germany is presented. An overview of the company is given, along with key facts including head quarter office, contact information, website address,...

  • New step for Bayer Schering.  // R&D Magazine;Jan2007, Vol. 49 Issue 1, p12 

    The article reports that Schering has been renamed to Bayer Schering Pharma AG following its acquisition by Bayer AG in July 2006. According to Werner Wenning, Bayer AG management board chairman, the firm is focusing on the next steps. Bayer Schering Pharma AG together with Bayer's...

  • NICE recommends all patients admitted to hospital are risk assessed for VTE.  // Operating Theatre Journal;Feb2010, Issue 233, p3 

    The article announces the launching of Bayer Schering Pharma AG with its implementation toolkit for the prevention of Venous Thromboembolism (VTE) in Great Britain.

  • Healthcare: Ethical Bayer Australia.  // Media: Asia's Media & Marketing Newspaper;11/19/2009, p33 

    The article reports on the use of public relations (PR) by Bayer Schering Pharma AG (BSP) as the main marketing platform to launch its oral contraceptives in Australia in 2009.

  • BiTE Advances to Preclinical Studies.  // Drug Discovery & Development;Nov2010, Vol. 13 Issue 9, p23 

    The article reports on the plans of Micromet Inc. to advance its BiTE antibody MT112/BAY2010112 into formal preclinical development in collaboration with Bayer Schering Pharma AG.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics